業績紹介

2024年 論文

  • Horiuchi K, Ikemura S, Sato T, Shimozaki K, Okamori S, Yamada Y, Yokoyama Y, Hashimoto M, Jinzaki M, Hirai I, Funakoshi T, Mizuno R, Oya M, Hirata K, Hamamoto Y, Terai H, Yasuda H, Kawada I, Soejima K, Fukunaga K: Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis: Oncologist, 29(1), e108-e117, 2024 Jan.
  • Fujiwara S, Kosaka T, Nishimoto Y, Kamisawa K, Watanabe K, Baba Y, Takeda T, Matsumoto K, Oya M: Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel: Prostate, 84(1), 25-31, 2024 Jan.
  • Saito T, Matsumoto K, Tanaka N, Fukumoto K, Yasumizu Y, Takeda T, Morita S, Kosaka T, Mizuno R, Asanuma H, Hara S, Oya M: Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy: Int Urol Nephrol, 56(1), 129-135, 2024 Jan.
  • Grimm MO, Oya M, Choueiri TK, Motzer RJ, Schmidinger M, Quinn DI, Gravis-Mescam G, Verzoni E, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L: Impact of Prior Cytoreductive　Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial: Eur Urol, 85(1), 8-12, 2024 Jan.
  • Daimon T, Bhattacharya A, Wang K, Haratake N, Nakashoji A, Ozawa H, Morimoto Y, Yamashita N, Kosaka T, Oya M, Kufe DW: MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells: Cell Death Discov, 10(1), 9, 2024 Jan.
  • Mizuno R, Yasumizu Y, Tanaka N, Takeda T, Morita S, Matsumoto K, Kosaka T, Asanuma H, Oya M: Anemia in patients ≥ 75 years with metastatic clear cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model: BMC Urol, 24(1), 13, 2024 Jan.
  • Hongo H, Kosaka T, Takayama KI, Baba Y, Yasumizu Y, Ueda K, Suzuki Y, Inoue S, Beltran H, Oya M: G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer: PNAS Nexus, 3(1), pgae002, 2024 Jan.
  • Yamashita R, Nakamura M, Notsu A, Asakura K, Usui K, Sakura Y, Shinsaka H, Matsuzaki M, Sugino T, Mizuno R, Niwakawa M, Oya M: Cumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy: BJUI Compass, 5(5), 483-489, 2024 Feb.
  • Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N: Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022: Clin Exp Nephrol, 28(2), 123-124, 2024 Feb.
  • Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022: Clin Exp Nephrol, 28(2), 85-122, 2024 Feb.
  • Shojo K, Takeda T, Akita H, Suzuki T, Mikami S, Shigeta K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Jinzaki M, Oya M: Prediction of pathological up-staging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: World J Urol, 42(1), 192, 2024 Mar.
  • Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H: Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART): Int J Urol, 31(3), 265-272, 2024 Mar.
  • Kamisawa K, Matsumoto K, Takeda T, Takamatsu K, Niwa N, Yasumizu Y, Tanaka N, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M: Impact of prostatic shape on the difficulty of robot-assisted laparoscopic radical prostatectomy: Asian J Endosc Surg, 17(2), e13291, 2024 Apr.
  • Izawa M, Takeda T, Anno T, Iwasawa T, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M: Risk factors for postoperative fever after laparoscopic adrenalectomy focusing on hormones produced: a case control study: BMC Urol, 24(1), 90, 2024 Apr.
  • Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N: Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project: BJC Rep, 2(1), 28, 2024 Apr.
  • Omura M, Kosaka T, Kobayashi H, Shigeta K, Matsumoto K, Hara S, Kikuchi E, Mikami S, Saya H, Sato Y, Oya M: Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy: Ann Surg Oncol, 31(5), 2951-2958, 2024 May.
  • Omura M, Kosaka T, Kobayashi H, Shigeta K, Matsumoto K, Hara S, Kikuchi E, Mikami S, Saya H, Sato Y, Oya M: ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer: Ann Surg Oncol, 31(6), 3914-3915, 2024 Jun.
  • Matsumoto K, Akita H, Hashiguchi A, Takeda T, Kosaka T, Fukumoto K, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Asanuma H, Oya M, Jinzaki M: Detection of the Highest-Grade Lesion in Multifocal Discordant Prostate Cancer by Multiparametric Magnetic Resonance Imaging: Clin Genitourin Cancer, 22(3), 102084, 2024 Jun.
  • Ezaki T, Hongo H, Takamatsu K, Tanaka N, Oya M: Concomitant Prostate Needle Biopsy and Laser Vaporization of the Prostate Could Be a Risk of Postoperative Hemoglobin Decline, a Retrospective Study: Res Rep Urol, 16, 123-129, 2024 Jun.
  • Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M: Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study: J Immunol, 213(1), 23-28, 2024 Jul.
  • Kaneko Y, Masuda T, Takamatsu K, Mikami S, Nakamura K, Nishihara H, Mizuno R, Tanaka N, Oya M: Volumetric imaging of the tumor microvasculature reflects outcomes and genomic states of clear cell renal cell carcinoma: J Pathol Clin Res, 10(4), e12388, 2024 Jul.
  • Fukumoto K, Kanatani S, Jaremko G, West Z, Li Y, Takamatsu K, Al Rayyes I, Mikami S, Niwa N, Axelsson TA, Tanaka N, Oya M, Miyakawa A, Brehmer M, Uhlén P: Three-dimensional imaging of upper tract urothelial carcinoma improves diagnostic yield and accuracy: JCI Insight, 9(14), e175751, 2024 Jul.
  • Karasawa H, Yasumizu Y, Kosaka T, Shimoi T, Oya M: Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation: IJU Case Rep, 7(5), 375-378, 2024 Jul.
  • Matsumoto K, Kosaka T, Takeda T, Fukumoto K, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Asanuma H, Oya M: Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI): Int J Clin Oncol, 29(8), 1198-1203, 2024 Aug.
  • Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators: Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma: N Engl J Med, 391(8), 710-721, 2024 Aug.
  • Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N: Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project: World J Urol, 42(1), 526, 2024 Sep.
  • Shojo K, Tanaka N, Murakami T, Anno T, Teranishi Y, Takamatsu K, Mikami S, Imamura T, Matsumoto K, Oya M: Multiplexed Spatial Imaging at the Single-Cell Level Reveals Mutually Exclusive Expression of B7 Family Proteins: Lab Invest, 104(10), 102131, 2024 Oct.
  • Takei T, Hamamura Y, Hongo H, Tashiro E, Imoto M, Kosaka T, Oya M: Selective killing of castration-resistant prostate cancer cells by formycin A via the ATF4-CHOP axis: Cancer Sci, 115(12), 3997-4007, 2024 Dec.
  • Kamitani R, Tanaka N, Anno T, Murakami T, Masuda T, Yasumizu Y, Takeda T, Morita S, Kosaka T, Mikami S, Matsumoto K, Oya M: Tumor immune microenvironment dynamics and outcomes of prognosis in non-muscle-invasive bladder cancer: Cancer Sci, 115(12), 3963-3972, 2024 Dec.
  • Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroğlu M, Gedye C, Buchschacher GL Jr, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Kim J, Oscroft E, Barker L, Degboe A, Clarke NW: Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial: Eur Urol Oncol, 7(6), 1394-1402, 2024 Dec.
  • Shigeta K, Matsumoto K, Kitaoka S, Omura M, Umeda K, Arita Y, Mikami S, Fukumoto K, Yasumizu Y, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Hara S, Oya M: Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma: Eur Urol Oncol, 7(6), 1338-1349, 2024 Dec.
  • Hayakawa N, Mizuno R, Tanaka T, Shiraishi Y, Matsumoto K, Kosaka T, Kikuchi E, Oya M: Comparing the efficacy of tadalafil and tamsulosin for managing erectile dysfunction and lower urinary tract symptoms in prostate brachytherapy patients: a prospective study: Prostate Int, 12(4), 231-237, 2024 Dec.
  • Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N: Genomic characterization of metastatic patterns in prostate cancer using circulating tumor DNA data from the SCRUM-Japan MONSTAR SCREEN project: J Liq Biopsy, 7, 100282, 2024 Dec.
  • Iwasa S, Asanuma H, Takahashi R, Fukumoto K, Yasumizu Y, Tanaka N, Takeda T, Matsumoto K, Morita S, Kosaka T, Mizuno R, Oya M: [AUGMENTED ONLAY BUCCAL MUCOSAL GRAFT URETEROPLASTY FOR URETERAL STRICTURE: A CASE REPORT]: Nihon Hinyokika Gakkai Zasshi, 115(1), 37-41, 2024.
業績紹介
慶應義塾大学泌尿器科学教室

160-8582 東京都新宿区信濃町35

TEL: 03-3353-1211（代表）

FAX: 03-3225-1985

  • 臨床研究へのご協力のお願い
  • NCDへのご協力のお願い
  • 慶應義塾大学病院
  • 慶應義塾大学医学部・医学研究科
  • 慶應義塾大学医学部 卒後臨床研修 専修医研修センター
  • 100周年
  • 慶應義塾大学
  • 三四会